Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment

22 Dec 2010

Abstract excerpt

The field of Philadelphia-chromosome-negative chronic myeloproliferative neoplasms (MPNs) has recently witnessed tremendous advances in the basic knowledge of disease pathophysiology that followed the identification of mutations in JAK2 and MPL. These discoveries led to a revision of the criteria employed for diagnosis by the World Health Organization. The prognostic role of the JAK2V617F mutation and of its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23556073
DOI: 10.1177/2040620710394474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatmentPMID 23556073Read ↗

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Semantic proximity Read ↗

Genotype-phenotype interactions in the myeloproliferative neoplasms.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

JAK2V617F allele burden in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.Semantic proximity Read ↗

High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia veraSemantic proximity Read ↗

Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience.Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.